BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 26, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Jan. 14, 2005
View Archived Issues
Avanir's Neurodex Now Ready For Neuropathic Pain Phase III
Avanir Pharmaceuticals Inc. received the FDA's blessing to begin a Phase III trial of Neurodex in pain, at the same time continuing work on its rolling new drug application in pseudobulbar affect. (BioWorld Today)
Read More
Raptiva Profitable For XOMA With Modification Of Genentech Deal
Read More
Adenosine A1 Receptor In Asthma Plays Cop, Robber
Read More
Oxxon In-Licenses Xenova Platform, Cancer Product
Read More
Holiday
Read More
Other News To Note
Read More